Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models.

Jing W, McAllister D, Vonderhaar EP, Palen K, Riese MJ, Gershan J, Johnson BD, Dwinell MB.

J Immunother Cancer. 2019 Apr 29;7(1):115. doi: 10.1186/s40425-019-0573-5.

2.

Diacylglycerol kinase ζ is a negative regulator of GPVI-mediated platelet activation.

Moroi AJ, Zwifelhofer NM, Riese MJ, Newman DK, Newman PJ.

Blood Adv. 2019 Apr 9;3(7):1154-1166. doi: 10.1182/bloodadvances.2018026328.

3.

Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma.

Bajor DL, Mick R, Riese MJ, Huang AC, Sullivan B, Richman LP, Torigian DA, George SM, Stelekati E, Chen F, Melenhorst JJ, Lacey SF, Xu X, Wherry EJ, Gangadhar TC, Amaravadi RK, Schuchter LM, Vonderheide RH.

Oncoimmunology. 2018 Aug 20;7(10):e1468956. doi: 10.1080/2162402X.2018.1468956. eCollection 2018.

4.

Frontline Science: PECAM-1 (CD31) expression in naïve and memory, but not acutely activated, CD8+ T cells.

Newman DK, Fu G, McOlash L, Schauder D, Newman PJ, Cui W, Rao S, Johnson BD, Gershan JA, Riese MJ.

J Leukoc Biol. 2018 Nov;104(5):883-893. doi: 10.1002/JLB.2HI0617-229RRR. Epub 2018 Jul 31.

PMID:
30063264
5.

Diacylglycerol kinase ζ (DGKζ) and Casitas b-lineage proto-oncogene b-deficient mice have similar functional outcomes in T cells but DGKζ-deficient mice have increased T cell activation and tumor clearance.

Wesley EM, Xin G, McAllister D, Malarkannan S, Newman DK, Dwinell MB, Cui W, Johnson BD, Riese MJ.

Immunohorizons. 2018 Apr 1;2(4):107-118. doi: 10.4049/immunohorizons.1700055.

6.

T Cells Deficient in Diacylglycerol Kinase ζ Are Resistant to PD-1 Inhibition and Help Create Persistent Host Immunity to Leukemia.

Jing W, Gershan JA, Holzhauer S, Weber J, Palen K, McOlash L, Pulakanti K, Wesley E, Rao S, Johnson BD, Riese MJ.

Cancer Res. 2017 Oct 15;77(20):5676-5686. doi: 10.1158/0008-5472.CAN-17-1309. Epub 2017 Sep 15.

7.

Immune Check Point Inhibition in Sarcomatoid Renal Cell Carcinoma: A New Treatment Paradigm.

Raychaudhuri R, Riese MJ, Bylow K, Burfeind J, Mackinnon AC, Tolat PP, Iczkowski KA, Kilari D.

Clin Genitourin Cancer. 2017 Oct;15(5):e897-e901. doi: 10.1016/j.clgc.2017.05.018. Epub 2017 May 25. No abstract available.

PMID:
28645484
8.

Diacylglycerol Kinases (DGKs): Novel Targets for Improving T Cell Activity in Cancer.

Riese MJ, Moon EK, Johnson BD, Albelda SM.

Front Cell Dev Biol. 2016 Oct 17;4:108. eCollection 2016. Review.

9.

Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy.

Rajasekaran K, Riese MJ, Rao S, Wang L, Thakar MS, Sentman CL, Malarkannan S.

Front Immunol. 2016 May 12;7:176. doi: 10.3389/fimmu.2016.00176. eCollection 2016. Review.

10.

The adhesion molecule PECAM-1 enhances the TGF-β-mediated inhibition of T cell function.

Newman DK, Fu G, Adams T, Cui W, Arumugam V, Bluemn T, Riese MJ.

Sci Signal. 2016 Mar 8;9(418):ra27. doi: 10.1126/scisignal.aad1242.

11.

TCR signaling intensity controls CD8+ T cell responsiveness to TGF-β.

Arumugam V, Bluemn T, Wesley E, Schmidt AM, Kambayashi T, Malarkannan S, Riese MJ.

J Leukoc Biol. 2015 Nov;98(5):703-12. doi: 10.1189/jlb.2HIMA1214-578R. Epub 2015 Jul 7.

12.

Regulatory T cells require TCR signaling for their suppressive function.

Schmidt AM, Lu W, Sindhava VJ, Huang Y, Burkhardt JK, Yang E, Riese MJ, Maltzman JS, Jordan MS, Kambayashi T.

J Immunol. 2015 May 1;194(9):4362-70. doi: 10.4049/jimmunol.1402384. Epub 2015 Mar 27.

13.

IQGAP1: insights into the function of a molecular puppeteer.

Abel AM, Schuldt KM, Rajasekaran K, Hwang D, Riese MJ, Rao S, Thakar MS, Malarkannan S.

Mol Immunol. 2015 Jun;65(2):336-49. doi: 10.1016/j.molimm.2015.02.012. Epub 2015 Feb 28. Review.

14.

Loss of PIKfyve in platelets causes a lysosomal disease leading to inflammation and thrombosis in mice.

Min SH, Suzuki A, Stalker TJ, Zhao L, Wang Y, McKennan C, Riese MJ, Guzman JF, Zhang S, Lian L, Joshi R, Meng R, Seeholzer SH, Choi JK, Koretzky G, Marks MS, Abrams CS.

Nat Commun. 2014 Sep 2;5:4691. doi: 10.1038/ncomms5691.

15.
16.

The ζ isoform of diacylglycerol kinase plays a predominant role in regulatory T cell development and TCR-mediated ras signaling.

Joshi RP, Schmidt AM, Das J, Pytel D, Riese MJ, Lester M, Diehl JA, Behrens EM, Kambayashi T, Koretzky GA.

Sci Signal. 2013 Nov 26;6(303):ra102. doi: 10.1126/scisignal.2004373.

17.

Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases.

Riese MJ, Wang LC, Moon EK, Joshi RP, Ranganathan A, June CH, Koretzky GA, Albelda SM.

Cancer Res. 2013 Jun 15;73(12):3566-77. doi: 10.1158/0008-5472.CAN-12-3874. Epub 2013 Apr 10.

18.

PERK utilizes intrinsic lipid kinase activity to generate phosphatidic acid, mediate Akt activation, and promote adipocyte differentiation.

Bobrovnikova-Marjon E, Pytel D, Riese MJ, Vaites LP, Singh N, Koretzky GA, Witze ES, Diehl JA.

Mol Cell Biol. 2012 Jun;32(12):2268-78. doi: 10.1128/MCB.00063-12. Epub 2012 Apr 9.

19.

Conditional deletion of SLP-76 in mature T cells abrogates peripheral immune responses.

Wu GF, Corbo E, Schmidt M, Smith-Garvin JE, Riese MJ, Jordan MS, Laufer TM, Brown EJ, Maltzman JS.

Eur J Immunol. 2011 Jul;41(7):2064-73. doi: 10.1002/eji.201040809. Epub 2011 Jun 7.

20.

Decreased diacylglycerol metabolism enhances ERK activation and augments CD8+ T cell functional responses.

Riese MJ, Grewal J, Das J, Zou T, Patil V, Chakraborty AK, Koretzky GA.

J Biol Chem. 2011 Feb 18;286(7):5254-65. doi: 10.1074/jbc.M110.171884. Epub 2010 Dec 7.

21.

Chemotherapy for patients with poor prognosis germ cell tumors.

Riese MJ, Vaughn DJ.

World J Urol. 2009 Aug;27(4):471-6. doi: 10.1007/s00345-009-0404-2. Epub 2009 Mar 28. Review.

PMID:
19330334
22.

Hematopoietic stem cell responsiveness to exogenous signals is limited by caspase-3.

Janzen V, Fleming HE, Riedt T, Karlsson G, Riese MJ, Lo Celso C, Reynolds G, Milne CD, Paige CJ, Karlsson S, Woo M, Scadden DT.

Cell Stem Cell. 2008 Jun 5;2(6):584-94. doi: 10.1016/j.stem.2008.03.012.

23.

Molecular heterogeneity of a type III cytotoxin, Pseudomonas aeruginosa exoenzyme S.

Maresso AW, Riese MJ, Barbieri JT.

Biochemistry. 2003 Dec 9;42(48):14249-57.

PMID:
14640693
24.

Intracellular localization modulates targeting of ExoS, a type III cytotoxin, to eukaryotic signalling proteins.

Pederson KJ, Krall R, Riese MJ, Barbieri JT.

Mol Microbiol. 2002 Dec;46(5):1381-90.

25.

Bacterial toxins that modify the actin cytoskeleton.

Barbieri JT, Riese MJ, Aktories K.

Annu Rev Cell Dev Biol. 2002;18:315-44. Epub 2002 Apr 2. Review.

PMID:
12142277
26.

ADP-ribosylation and functional effects of Pseudomonas exoenzyme S on cellular RalA.

Fraylick JE, Riese MJ, Vincent TS, Barbieri JT, Olson JC.

Biochemistry. 2002 Jul 30;41(30):9680-7.

PMID:
12135390
27.
28.

Auto-ADP-ribosylation of Pseudomonas aeruginosa ExoS.

Riese MJ, Goehring UM, Ehrmantraut ME, Moss J, Barbieri JT, Aktories K, Schmidt G.

J Biol Chem. 2002 Apr 5;277(14):12082-8. Epub 2002 Jan 30.

29.

Supplemental Content

Loading ...
Support Center